Pregnancy outcomes in subjects exposed to certolizumab pegol

Megan E.B. Clowse, Douglas C. Wolf, Frauke Förger, John J. Cush, Amanda Golembesky, Laura Shaughnessy, Dirk De Cuyper, Uma Mahadevan

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective. To provide information on pregnancy outcomes in women receiving certolizumab pegol (CZP). Methods. The UCB Pharma safety database was searched for pregnancies through to September 1, 2014. Reports for maternal and paternal CZP exposure were included and outcomes examined, and data on CZP exposure, pregnancy, comorbidities, and infant events were extracted by 2 independent reviewers. Concomitant medications and disease activity were reviewed for clinical trial patients. Results. Of 625 reported pregnancies, 372 (59.5%) had known outcomes. Paternal exposure pregnancies (n = 33) reported 27 live births, 4 miscarriages, 1 induced abortion, and 1 stillbirth. Maternal exposure pregnancies (n = 339) reported 254 live births, 52 miscarriages, 32 induced abortions, and 1 stillbirth. Almost all reported pregnancies had exposure to CZP in the first trimester, when organogenesis takes place, and a third of them continued the drug into the second and/or third trimesters. The most frequent indications for maternal CZP use were Crohn disease (192/339) and rheumatic diseases (118/339). Twelve cases of congenital malformation and a single neonatal death were reported. Conclusion. Analysis of pregnancy outcomes after exposure to CZP supports previous reports, suggesting a lack of harmful effect of maternal CZP exposure on pregnancy outcomes. However, additional data from a larger number of outcomes after exposure and studies including an unexposed comparison group are required to fully evaluate CZP safety and tolerability in pregnancy.

Original languageEnglish (US)
Pages (from-to)2270-2278
Number of pages9
JournalJournal of Rheumatology
Volume42
Issue number12
DOIs
StatePublished - Dec 2015
Externally publishedYes

Fingerprint

Pregnancy Outcome
Pregnancy
Stillbirth
Induced Abortion
Mothers
Live Birth
Spontaneous Abortion
Paternal Exposure
Safety
Maternal Exposure
Organogenesis
Certolizumab Pegol
Third Pregnancy Trimester
Second Pregnancy Trimester
First Pregnancy Trimester
Rheumatic Diseases
Crohn Disease
Comorbidity
Clinical Trials
Databases

Keywords

  • Certolizumab pegol
  • Congenital malformations
  • Miscarriage
  • Pregnancy

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Clowse, M. E. B., Wolf, D. C., Förger, F., Cush, J. J., Golembesky, A., Shaughnessy, L., ... Mahadevan, U. (2015). Pregnancy outcomes in subjects exposed to certolizumab pegol. Journal of Rheumatology, 42(12), 2270-2278. https://doi.org/10.3899/jrheum.140189

Pregnancy outcomes in subjects exposed to certolizumab pegol. / Clowse, Megan E.B.; Wolf, Douglas C.; Förger, Frauke; Cush, John J.; Golembesky, Amanda; Shaughnessy, Laura; De Cuyper, Dirk; Mahadevan, Uma.

In: Journal of Rheumatology, Vol. 42, No. 12, 12.2015, p. 2270-2278.

Research output: Contribution to journalArticle

Clowse, MEB, Wolf, DC, Förger, F, Cush, JJ, Golembesky, A, Shaughnessy, L, De Cuyper, D & Mahadevan, U 2015, 'Pregnancy outcomes in subjects exposed to certolizumab pegol', Journal of Rheumatology, vol. 42, no. 12, pp. 2270-2278. https://doi.org/10.3899/jrheum.140189
Clowse MEB, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L et al. Pregnancy outcomes in subjects exposed to certolizumab pegol. Journal of Rheumatology. 2015 Dec;42(12):2270-2278. https://doi.org/10.3899/jrheum.140189
Clowse, Megan E.B. ; Wolf, Douglas C. ; Förger, Frauke ; Cush, John J. ; Golembesky, Amanda ; Shaughnessy, Laura ; De Cuyper, Dirk ; Mahadevan, Uma. / Pregnancy outcomes in subjects exposed to certolizumab pegol. In: Journal of Rheumatology. 2015 ; Vol. 42, No. 12. pp. 2270-2278.
@article{d732c3c7157145abb9cc850b32a3a8e4,
title = "Pregnancy outcomes in subjects exposed to certolizumab pegol",
abstract = "Objective. To provide information on pregnancy outcomes in women receiving certolizumab pegol (CZP). Methods. The UCB Pharma safety database was searched for pregnancies through to September 1, 2014. Reports for maternal and paternal CZP exposure were included and outcomes examined, and data on CZP exposure, pregnancy, comorbidities, and infant events were extracted by 2 independent reviewers. Concomitant medications and disease activity were reviewed for clinical trial patients. Results. Of 625 reported pregnancies, 372 (59.5{\%}) had known outcomes. Paternal exposure pregnancies (n = 33) reported 27 live births, 4 miscarriages, 1 induced abortion, and 1 stillbirth. Maternal exposure pregnancies (n = 339) reported 254 live births, 52 miscarriages, 32 induced abortions, and 1 stillbirth. Almost all reported pregnancies had exposure to CZP in the first trimester, when organogenesis takes place, and a third of them continued the drug into the second and/or third trimesters. The most frequent indications for maternal CZP use were Crohn disease (192/339) and rheumatic diseases (118/339). Twelve cases of congenital malformation and a single neonatal death were reported. Conclusion. Analysis of pregnancy outcomes after exposure to CZP supports previous reports, suggesting a lack of harmful effect of maternal CZP exposure on pregnancy outcomes. However, additional data from a larger number of outcomes after exposure and studies including an unexposed comparison group are required to fully evaluate CZP safety and tolerability in pregnancy.",
keywords = "Certolizumab pegol, Congenital malformations, Miscarriage, Pregnancy",
author = "Clowse, {Megan E.B.} and Wolf, {Douglas C.} and Frauke F{\"o}rger and Cush, {John J.} and Amanda Golembesky and Laura Shaughnessy and {De Cuyper}, Dirk and Uma Mahadevan",
year = "2015",
month = "12",
doi = "10.3899/jrheum.140189",
language = "English (US)",
volume = "42",
pages = "2270--2278",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "12",

}

TY - JOUR

T1 - Pregnancy outcomes in subjects exposed to certolizumab pegol

AU - Clowse, Megan E.B.

AU - Wolf, Douglas C.

AU - Förger, Frauke

AU - Cush, John J.

AU - Golembesky, Amanda

AU - Shaughnessy, Laura

AU - De Cuyper, Dirk

AU - Mahadevan, Uma

PY - 2015/12

Y1 - 2015/12

N2 - Objective. To provide information on pregnancy outcomes in women receiving certolizumab pegol (CZP). Methods. The UCB Pharma safety database was searched for pregnancies through to September 1, 2014. Reports for maternal and paternal CZP exposure were included and outcomes examined, and data on CZP exposure, pregnancy, comorbidities, and infant events were extracted by 2 independent reviewers. Concomitant medications and disease activity were reviewed for clinical trial patients. Results. Of 625 reported pregnancies, 372 (59.5%) had known outcomes. Paternal exposure pregnancies (n = 33) reported 27 live births, 4 miscarriages, 1 induced abortion, and 1 stillbirth. Maternal exposure pregnancies (n = 339) reported 254 live births, 52 miscarriages, 32 induced abortions, and 1 stillbirth. Almost all reported pregnancies had exposure to CZP in the first trimester, when organogenesis takes place, and a third of them continued the drug into the second and/or third trimesters. The most frequent indications for maternal CZP use were Crohn disease (192/339) and rheumatic diseases (118/339). Twelve cases of congenital malformation and a single neonatal death were reported. Conclusion. Analysis of pregnancy outcomes after exposure to CZP supports previous reports, suggesting a lack of harmful effect of maternal CZP exposure on pregnancy outcomes. However, additional data from a larger number of outcomes after exposure and studies including an unexposed comparison group are required to fully evaluate CZP safety and tolerability in pregnancy.

AB - Objective. To provide information on pregnancy outcomes in women receiving certolizumab pegol (CZP). Methods. The UCB Pharma safety database was searched for pregnancies through to September 1, 2014. Reports for maternal and paternal CZP exposure were included and outcomes examined, and data on CZP exposure, pregnancy, comorbidities, and infant events were extracted by 2 independent reviewers. Concomitant medications and disease activity were reviewed for clinical trial patients. Results. Of 625 reported pregnancies, 372 (59.5%) had known outcomes. Paternal exposure pregnancies (n = 33) reported 27 live births, 4 miscarriages, 1 induced abortion, and 1 stillbirth. Maternal exposure pregnancies (n = 339) reported 254 live births, 52 miscarriages, 32 induced abortions, and 1 stillbirth. Almost all reported pregnancies had exposure to CZP in the first trimester, when organogenesis takes place, and a third of them continued the drug into the second and/or third trimesters. The most frequent indications for maternal CZP use were Crohn disease (192/339) and rheumatic diseases (118/339). Twelve cases of congenital malformation and a single neonatal death were reported. Conclusion. Analysis of pregnancy outcomes after exposure to CZP supports previous reports, suggesting a lack of harmful effect of maternal CZP exposure on pregnancy outcomes. However, additional data from a larger number of outcomes after exposure and studies including an unexposed comparison group are required to fully evaluate CZP safety and tolerability in pregnancy.

KW - Certolizumab pegol

KW - Congenital malformations

KW - Miscarriage

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84948750073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948750073&partnerID=8YFLogxK

U2 - 10.3899/jrheum.140189

DO - 10.3899/jrheum.140189

M3 - Article

C2 - 26523031

AN - SCOPUS:84948750073

VL - 42

SP - 2270

EP - 2278

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 12

ER -